FEB 27, 2019 01:30 PM PST

Advanced Liver Tissue Model for Improved in Vitro Prediction

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Chief Operating Officer, HµREL Corporation
    Biography
      Leading Hurel's commercial operations, Matthew K. Shipton brings to the Company a skill for implementing sales-driven business strategies, an extensive track record of meeting and surpassing targeted sales objectives, and a passion for translating customer needs into solutions that exceed customer expectations. In addition to his role of leading the Company's outreach and relationships with customers; serving as a customer advocate inside the Company, he works closely with Hurel's R&D team to articulate market needs and identify opportunities for new products. Over the past fourteen years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Immediately prior to joining Hurel, he served as the Central and Southern U.S. Regional Sales Manager for Bioreclamation IVT (formerly CelsisIVT), where he was responsible for leading regional revenue generation and new account growth. In that capacity Mr. Shipton organized and led multiple, dedicated strategic initiatives, including establishing the CelsisIVT partnership with the Research Institute for Liver Disease (RILD) in China, as well as consummating long-term supply agreements with a number of the major pharmaceutical companies. Prior to CelsisIVT, Mr. Shipton served as Director of North American Business Development for Cyprotex, PLC, a UK-based contract research organization ("CRO") specializing in preclinical drug discovery services. Before Cyprotex, he was Regional Sales Manager for CellzDirect, a Durham, NC based provider of primary hepatic cell-based products and services which in 2008 was acquired by Invitrogen (now Thermo Fisher). Mr. Shipton holds Master's and Bachelor's Degrees in Chemistry from, respectively, North Carolina State University and Youngstown State University.

    Abstract:

    Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost in the first hours or days of culture in many in vitro hepatic models, such models are of limited use in instances where meaningfully predictive simulation of a compound’s properties require that the in vitro model maintain such function stably over longer time periods, such as where compounds clear slowly, where metabolites are generated over extended periods of time, where membrane polarization is required for biliary canalicular formation, or where cellular conditions may cumulate after repeated dosing, such as in cholestatic toxicities. To address this limitation, more advanced liver models have been developed and extensively characterized.  These long-term models have been shown to more accurately predict intrinsic clearance, metabolite generation, and toxicity profiles.

    Learning Objectives:

    1.  Learn about advanced liver models for improved in vitro prediction.  
    2.  Learn about the next wave of organ-on-chip with microfluidic advancements.  


    Show Resources
    You May Also Like
    NOV 15, 2018 10:00 AM PST
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    FEB 26, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 26, 2019 09:00 AM PST
    DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
    FEB 20, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 20, 2019 09:00 AM PST
    DATE:  February 20, 2019TIME:  9:00am PST  ...
    FEB 27, 2019 08:00 AM PST
    C.E. CREDITS
    FEB 27, 2019 08:00 AM PST
    DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
    MAR 20, 2019 09:00 AM PDT
    C.E. CREDITS
    MAR 20, 2019 09:00 AM PDT
    DATE:  March 20, 2019TIME:  9:00am PDT...
    OCT 09, 2018 08:00 AM PDT
    C.E. CREDITS
    OCT 09, 2018 08:00 AM PDT
    DATE: October 9, 2018TIME: 08:00am PDT, 11:00pm EDT Have you ever wondered what to consider when you are selecting ancillary materials for your cell therapy clinical research...
    Loading Comments...
    Show Resources